MDX-1097
MDX-1097 (formerly called IST-1097, now called KappaMab) is a monoclonal antibody therapy being developed by the Australian biotechnology company HaemaLogiX Ltd for the treatment of multiple myeloma.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
MDX-1097 (formerly called IST-1097, now called KappaMab) is a monoclonal antibody therapy being developed by the Australian biotechnology company HaemaLogiX Ltd for the treatment of multiple myeloma. In 2023, results were reported from a Phase IIb trial (AMaRC 01-16) assessing KappaMab alone and in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory kappa light chain-restricted multiple myeloma, a type of white blood cell cancer.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1377198786 under CC BY-SA 4.0; modifications have been made.